ABSTRACT: As part of a program to develop a small molecule inhibitor of LIMK, a series of aminothiazole inhibitors were discovered by high throughput screening. Scaffold hopping and subsequent SAR directed development led to a series of low nanomolar inhibitors of LIMK1 and LIMK2 that also inhibited the direct biomarker p-cofilin in cells and inhibited the invasion of MDA MB-231-luc cells in a matrigel inverse invasion assay.
■ INTRODUCTION
Tumour cell invasion and metastasis are the primary causes of mortality in cancer patients. During progression of tumor cells to a metastatic phenotype, they undergo a series of changes that begin with loss of contact inhibition and increased motility, allowing them to migrate from the primary tumor site, invade distant organs, and induce neovascularization, resulting in metastasis. 1 Despite numerous developments, cancer cell invasion and metastasis is still a poorly studied process. Most strategies to treat cancer do not rely on inhibiting invasion and metastasis as the primary phenotype due to the requirement for lengthy and complicated clinical trials. However, a detailed understanding of the drivers of cancer cell invasion and migration is essential to develop new treatments for cancer patients.
The LIM kinases (LIMK1 and LIMK2; collectively LIMK) are TKL kinases that act downstream of Rho GTPases. LIM kinases phosphorylate and inactivate the filamentous-actin severing protein cofilin. Cycles of cofilin inactivation and activation enable dynamic actin rearrangements that are required for cell motility (Figure 1 ). Once phosphorylated at Ser3 by the LIM kinases, cofilin can no longer bind to actin, leading to the accumulation of actin polymers. LIM kinases are therefore centrally positioned regulators of actin cytoskeletal dynamics and also play important roles in microtubule organization. 2, 3 LIMK1 has been reported to play a key regulatory role in tumor cell invasion and the level of LIMK1 is increased in invasive breast, 4 prostate, 5 and pancreatic 6 
■ RESULTS AND DISCUSSION
We used a commercially available kinase Glo kit measuring ATP depletion using full length LIMK and cofilin to screen 60000 compounds.
14 From this we identified two lead series, a series of pyrimidines that our partners CTx developed 15, 16 and a series of aminothiazoles exemplified by 1 LIMK1 IC 50 = 4 μM ( Figure 2 ) as modestly potent inhibitors of LIMK1. Although these compounds could be improved in terms of their isolated enzyme potency, no evidence of activity in the cellular assay was observed. In removing the amino functionality, we reasoned that we could improve the cellular potency by reducing the H bond count. We also removed the undesirable ketone functionality due to concerns over the potential chemical reactivity toward nucleophiles, replacing it with a variety of bioisosteric replacements. This led to pyridine 2, a compound that was similarly potent to the original hit 1. Bristol-Myers Squibb reported that substituted pyrazoles with an aryl di-ortho chloro group were potent LIMK inhibitors. 13 Similarly we found that pyridines substituted with aryl rings adjacent to the thiazole ring provided substantial improvements in potency as in 3a, which had a LIMK1 potency of 15 nM. Even more importantly, compound 3a modulated the target pcofilin in the breast cell line ZR-75−1 with an IC 50 = 3 μM.
To better understand the binding mode, we created a homology model of the kinase domain of hLIMK1 based on cSrc (PDB code 1Y57.pdb) as a template. hLIMK shares 33.5% sequence identity and 50.6% sequence similarity with the c-Src template. While there are some sequence inserts in the activation loop region (LIMK1 compared with c-Src) the rest of the sequences align well with no major inserts or deletions.
The improvements in potency were explained by docking 3a into the homology model ( Figure 3 ). The amino thiadiazole in 1, 2, and 3a can form the key donor−acceptor interaction to the Ile428, hinge residue. The pyridyl nitrogen present in 2 and 3a is well placed to interact with the salt bridge Lys380 residue. This agreed well with the SAR because the other pyridine isomers 4, 5, and 6 were much less potent than 3a ( Figure 4 ). While it is not considered to be contributing greatly to affinity, the chlorine atom was postulated to be making a halogen bond interaction to the Val 378 residue.
To understand the SAR and key binding interactions, we set out to synthesize analogues of the cell active lead 3a. A variety of synthetic strategies were employed to allow late stage modifications of either the aryl ring (Scheme 1) or the amine side chain attached to the aminothiazole (Schemes 2 and 3).
Starting from the commercially available 3-bromopyridine-4-carbaldehyde 7 and reducing to the alcohol 8, chlorination with thionyl chloride to the benzyl chloride 9 proceeded smoothly. The thiazole ring could then be constructed by heating in acetonitrile with triethylamine and the appropriate amidines 10a−10c to provide the thiazoles 11a−11c. Protection of 11a with a Boc group allowed the introduction of a range of aryl groups via a Suzuki coupling to furnish after deprotection with TFA the final compounds 3a−3h. Compound 3i was prepared by an alternative route from 11b by diBoc protection to give 13 followed by Suzuki coupling to afford 14a, which could then be 
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Brief Article converted to the chloride 15 by diazotization in hydrochloric acid. Displacement with N-propylmethylamine gave the final target 3i.
Initial SAR modifications focused mainly on the aryl ring ( Table 1 ) and demonstrated that the presence of an ortho substituent was required to provide activity, in particular where the group was ortho chloro as shown in entry 3a. The ortho chloro group could be replaced with a methyl or trifluoro methyl, although larger groups such as iso-propyl resulted in large losses in LIMK1 potency. Removal of the propyl side chain as in entry 14a or methylation of the NH as in entry 3i resulted in large losses in potency, with the latter result being consistent with the proposed binding mode where the NH forms a key donor interaction to the hinge region of the kinase (Figure 3) .
The amine side chain could be modified (Scheme 2) by diBoc protection of 11b to give 13 followed by a Suzuki coupling gave the Boc protected and the unprotected compounds 14a and 16, respectively. The monoBoc protected aminothiazole 14a could be derivatized using a Mitsunobu coupling, providing a convenient method to deliver benzylamines 3l and 3m. Alternatively, 11b could be monoBoc protected to give 17 and the amine side chain could be introduced via a Mitsunobu coupling to give 18a and 18b. Suzuki couplings provided access to the targets 3j and 3k. Using an analogous strategy that was employed in (Scheme 1) N-aryl analogues could be introduced by Boc protection of 11c to afford 19 and subsequent Suzuki coupling to yield 3n.
To allow further diversification of the aminothiazole side chain at the last step, the aryl rings could be introduced on the 
Brief Article alcohol intermediates 20a and 20b (Scheme 3) followed by chlorination to provide 21a and 21b, thiazole formation with 10b or 10d provided final compound 3o and intermediates 14b−14c. This then allowed for a series of amides to be prepared 22a−22d. The N-aryl analogue 3n in particular was very potent, providing a compound that was submicromolar in the p-cofilin cellular assay (Table 2) . Smaller alkyl groups such as ethyl 3j
were less potent compared to iso-butyl 3k and benzylamines 3l and 3m. Amides 22a−22d were also well tolerated, particularly 22b, which was 0.8 μM in the p-cofilin cellular assay.
The ADME properties of the compounds required optimization, in particular the alkyl substituted analogues were liable to high metabolic turnover in vitro. However, the propyl group could be replaced with N-aryl analogues and amide groups. The amide analogue 22d in particular had lower in vitro microsomal turnover (Table 3) .
To understand the functional effects of the compounds, we employed a 3D inverse invasion assay 17 to measure the inhibition of invasion of cells into a matrigel matrix. To purely understand the metastatic phenotype, it was necessary to select nontoxic compounds, so cell viability at 10 μM was measured. We used an MTT cytotoxicity assay to select four compounds for further investigation based on their lack of cytotoxic effects (Table 4) . To measure the invasive phenotype, MDA MB-231-luc cells were plated on the underside of a transwell filter plate. The ability of cells to invade was measured by confocal microscopy of sections through a matrigel plug. The percentage inhibition of invasion was measured as a function of the proportion of cells that invaded more than 60 μm into the matrigel plug compared to cells that invaded less than 60 μm, relative to the control. Compounds 3k, 22c, 22d, and 3o all inhibited the invasion of the cells through matrigel at a concentration of 3 μM while not significantly affecting cell viability even at the higher compound concentration of 10 μM. Compound 3o was found to be the most effective at inhibiting invasion. However, the more selective compound 22d also significantly inhibited the invasion of the cells by 52% at 60 μm. In addition, two other compounds, 3k and 22c, also inhibited invasion without having a marked effect on cell viability.
To measure selectivity against the LIMK2 isoform, we developed an assay using a lanthabind format. The compounds were similarly potent Vs LIMK2 as LIMK1 (Table 3 ). The lead compounds were also profiled for their selectivity against a broader panel of 442 kinases using KINOMEscan at Millipore (now DisoveRx). The selectivity of 22d, 3o, and 22c is represented in the kinome phylogenetic trees from screening at 10 μM inhibitor concentration ( Figure 5 ). Selectivity scores were calculated as the number of nonmutant kinases with % activity relative to control <35/number of nonmutant kinases tested. Compounds 22d and 22c were the particularly selective, with selectivity S(35) scores of 0.083 and 0.132, respectively. Compound 22d showed >90% inhibition against the following 15/442 kinases at 10 μM: AMPKα1, AMPKα2, CASK, CDK2, CDK7, CDKL2, DDR2, ERK8, MAK, PAK3, PCTK3, PIP5K2C, STK16 as well as LIMK1 and LIMK2.
■ CONCLUSION
In summary, we have developed a series of novel LIMK inhibitors that are effective in inhibiting cellular invasion through a 3D matrix. An additional publication by Olson et al. 18 will detail further biological data using compounds 22d and 3o (also known as CRT0105446 and CRT0105950, respectively) to investigate the effects of LIMK inhibition on microtubule 
